Confronto
Leuprorelin vs. LL-37
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
53714-56-0
597562-32-8
Peso molecolare
1209.4 g/mol
4493.33 g/mol
Emivita
3 h
nessun dato
Sequenza
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMeccanismo d'azione
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
1
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
3
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Leuprorelin and LL-37?
- Leuprorelin is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or LL-37?
- The highest available evidence level is "RCT sull'uomo" for Leuprorelin and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and LL-37 in Germany and the United States?
- Germania: Leuprorelin — Su prescrizione, LL-37 — Solo ricerca. Stati Uniti: Leuprorelin — Su prescrizione, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.